Cognition Therapeutics, Inc. (CGTX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Lisa Ricciardi | CEO, President & Director | 951.74k | -- | 1960 |
| Mr. John Brendan Doyle | Chief Financial Officer | 619.94k | -- | 1977 |
| Dr. Anthony O. Caggiano M.D., Ph.D. | Chief Medical Officer and Head of R&D | 676.37k | -- | 1970 |
| Dr. Steven A. Weissman Ph.D. | VP & Head of CMC | -- | -- | -- |
| Ms. Anita Cornet | Head of Quality | -- | -- | -- |
| Mr. Bobby Horn | Corporate Controller | -- | -- | -- |
Cognition Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 25
Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Corporate Governance
Upcoming Events
August 6, 2025 at 12:30 PM UTC - August 11, 2025 at 12:30 PM UTC
Cognition Therapeutics, Inc. Earnings Date